Monthly Or Bust: Zalbin's Chances For Approval Likely Rest On Monthly Use Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA indicates risk-to-benefit ratio is insufficient to approve Human Genome Sciences' next-generation interferon for biweekly dosing.
You may also be interested in...
Novartis And HGS Close The Door On Zalbin
Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.
Novartis And HGS Close The Door On Zalbin
Development of hepatitis C drug concluded after FDA "complete response" letter and disappointing monthly dosing data.
FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
Almost one-third fewer novel product applications are on FDA's user fee calendar for the second half of 2010 as compared to the docket at the same point in 2009, a dearth that could imperil the slow but steady improvement in annual new molecular entity and novel biologic approvals after the nadirs reached earlier in the decade